![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DOJ Charges Glenmark In Ongoing Generic Price-Fixing Investigation
DOJ Charges Glenmark In Ongoing Generic Price-Fixing Investigation
July 2, 2020
The Department of Justice (DOJ) has charged Indian drugmaker Glenmark Pharmaceuticals with allegedly conspiring to increase prices on the cholesterol drug pravastin.
The complaint in a Pennsylvania federal court alleges that Glenmark conspired with Apotex and another unnamed company to fix prices for the generic drug from May 2013 to December 2015. The suit alleges that the companies gained $200 million for the scheme.
Glenmark is the fifth company over the past 13 months to be charged as part of a DOJ investigation.
Upcoming Events
-
21Oct